2023年6月23日

生物技術供應商Abcam Plc的創始人正在尋求替代它的一些董事會成員,說這是探索戰略選擇包括潛在的銷售。6月23日,2023年發表的文章的作者:•2分鍾閱讀文章內容(彭博社)——Abcam Plc、生物技術供應商的創始人正在尋求替代它的一些董事會成員,說這是探索戰略選擇包括潛在的銷售。我們道歉,但這個視頻沒有負載。嚐試刷新瀏覽器,或生命科學公司Abcam探索銷售在創始人戰鬥後回到視頻與投資者,英國公司決定立即開始“全麵過程”來評估廣泛的股東價值最大化的選擇,這周五在一份聲明中說。Abcam董事會聘請了Lazard ltd .)和摩根士丹利(Morgan Stanley)在審查,建議根據聲明。廣告2本內容僅留給用戶訂閱閱讀最新消息在你的城市和整個加拿大。獨家文章由凱文•卡邁克爾維多利亞井,傑克埃德米斯頓,加布裏埃爾·弗裏德曼和其他人。日常內容從英國《金融時報》,世界領先的全球商業出版物。無限上網讀金融郵報》的文章,National Post和15新聞網站在加拿大有一個帳戶。國家發布電子報,打印版的電子副本在任何設備,分享和評論。 Daily puzzles, including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others. Daily content from Financial Times, the world's leading global business publication. Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. REGISTER TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. or Article content Financial Post Top Stories Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc. Email Address Sign Up By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300 Thanks for signing up! A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Financial Post Top Stories will soon be in your inbox. We encountered an issue signing you up. Please try again Article content There can be no assurances about the outcome of the review, Abcam said in the statement. The company’s American depositary shares jumped as much as 13% in pre-market trading in New York. Before Friday, they had gained 30% this year, giving Abcam a market value of about $4.7 billion. Bloomberg News reported last week that Abcam was in talks on a potential sale and had attracted interest from suitors including some of the largest US suppliers of life-sciences tools. The Cambridge, England-based company previously announced it had received multiple takeover approaches over the past few weeks. Abcam will hold an extraordinary general meeting July 12 at the request of founder Jonathan Milner to consider his proposals to remove three directors and name himself executive chairman. Advertisement 3 Article content Milner issued an open letter to Abcam investors earlier Friday, saying if he’s elected he would create a strategic review committee to explore deal opportunities. He argued in the letter than Abcam’s incumbent directors lack a “shareholder mindset” and aren’t incentivized to drive a deal at the right price. Abcam runs an online store selling a variety of protein research tools to life scientists, ranging from reagents and cellular assays to enzymes and imaging products and is sometimes referred to as the “Amazon of antibodies.” Milner, a British scientist who founded Abcam, is one of its largest shareholders with a 6.3% stake. Investors view Thermo Fisher Scientific Inc., Danaher Corp. and Germany’s Merck KGaA as the most likely trade bidders for Abcam, Royal Bank of Canada wrote in a research report earlier this month. (Updates with share reaction in third paragraph.)